Recurrent Non-small Cell Lung Cancer Terminated Phase 1 Trials for Dovitinib (DB05928)

Also known as: Non-Small Cell Lung Cancer Recurrent / Lung cancer non-small cell recurrent

IndicationStatusPhase
DBCOND0028805 (Recurrent Non-small Cell Lung Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01515969Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC)Treatment